Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Librium. Every FDA application for this active ingredient: 2 branded and 77 generic.
As of Nov 15, 2026, FDA lists 79 applications for Chlordiazepoxide Hydrochloride (sold as Librium), first approved Feb 24, 1960, with 0 new uses approved and 0 published complete response letters.
First approved: Feb 24, 1960
Applications: 79
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $952K
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Chlordiazepoxide HCl
Part D
$952K
-7%
25,010
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
CHLORDIAZEPOXIDE 10 MG CAPSULE: $0.144 per unitGeneric · +2% in a year
CHLORDIAZEPOXIDE 25 MG CAPSULE: $0.156 per unitGeneric · -3% in a year
CHLORDIAZEPOXIDE 5 MG CAPSULE: $0.186 per unitGeneric · +1% in a year
FDA Drug Safety Communications
One communication since 2020 that name this drug; see all communications
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Roxane
Parke Davis
Abbott
Impax Labs
Teva
Mylan